Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Georgina V. Long*, Robyn P. M. Saw, Serigne Lo, Omgo E. Nieweg, Kerwin F. Shannon, Maria Gonzalez, Alexander Guminski, Jenny H. Lee, Hansol Lee, Peter M. Ferguson, Robert V. Rawson, James S. Wilmott, John F. Thompson, Richard F. Kefford, Sydney Ch'ng, Jonathan R. Stretch, Louise Emmett, Rony Kapoor, Helen Rizos, Andrew J. SpillaneRichard A. Scolyer, Alexander M. Menzies

*Corresponding author for this work

    Research output: Contribution to journal › Article › peer-review

    134 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences